A retrospective claims analysis in JMCP found that patients who received an outpatient opioid prescription following surgery had significantly increased health care utilization and costs for the following year.
A retrospective claims analysis in JMCP found that patients who received an outpatient opioid prescription following surgery had significantly increased health care utilization and costs for the following year.
Extended-release opioid agonists and antagonists represent an alternative treatment strategy for opioid use disorder. However their value is low for the money, according to this summary of an ICER analysis published in JMCP.
The benefits of extended release opioid agonists and antagonists in the highly personalized space of opioid use disorder treatment are described in this JMCP article by the CMO of Drug & Alcohol Treatment Centers, Pathway Healthcare.
The benefits of extended release opioid agonists and antagonists in the highly personalized space of opioid use disorder treatment are described in this JMCP article by the CMO of Drug & Alcohol Treatment Centers, Pathway Healthcare.